Berkeley Capital Partners LLC increased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 73.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,851 shares of the pharmaceutical company’s stock after acquiring an additional 5,456 shares during the quarter. Berkeley Capital Partners LLC’s holdings in GlaxoSmithKline PLC were worth $522,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. FMR LLC lifted its stake in shares of GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares during the period. Fisher Asset Management LLC lifted its stake in shares of GlaxoSmithKline PLC by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares during the period. Renaissance Technologies LLC lifted its stake in shares of GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares during the period. Hotchkis & Wiley Capital Management LLC lifted its stake in shares of GlaxoSmithKline PLC by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after acquiring an additional 322,700 shares during the period. Finally, Federated Investors Inc. PA lifted its stake in shares of GlaxoSmithKline PLC by 22.7% in the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after acquiring an additional 833,501 shares during the period. 9.84% of the stock is currently owned by institutional investors.
GlaxoSmithKline PLC (NYSE GSK) traded up $0.10 during midday trading on Monday, hitting $35.16. The stock had a trading volume of 2,666,491 shares, compared to its average volume of 3,439,725. The company has a market capitalization of $85,170.00, a P/E ratio of 12.43, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00. GlaxoSmithKline PLC has a 52-week low of $34.72 and a 52-week high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.73%. GlaxoSmithKline PLC’s payout ratio is currently 157.94%.
Several equities analysts have issued reports on the company. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Finally, Argus reissued a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $44.33.
ILLEGAL ACTIVITY NOTICE: This story was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.truebluetribune.com/2017/11/20/glaxosmithkline-plc-gsk-position-boosted-by-berkeley-capital-partners-llc.html.
In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.00% of the company’s stock.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.